Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10839393 | 1.00 | OPRL1 (0.50) | OPRL1KCNH2SIGMAR1HTR2AHTR2C | |
| SCHEMBL2882813 | 1.00 | OPRL1 (0.50) | OPRL1KCNH2SIGMAR1HTR2AHTR2C | |
| SCHEMBL2877400 | 0.85 | SIGMAR1 (0.44) | OPRL1KCNH2SIGMAR1HTR2AHTR2C | |
| SCHEMBL27706698 | 0.84 | SIGMAR1 (0.47) | SIGMAR1HTR2CHTR2B | |
| SCHEMBL5459468 | 0.80 | SLC6A3 (0.54) | — | |
| SCHEMBL4759732 | 0.80 | SLC6A3 (0.54) | — | |
| SCHEMBL4759736 | 0.80 | SLC6A3 (0.54) | — | |
| SCHEMBL5459465 | 0.80 | SLC6A3 (0.54) | — | |
| SCHEMBL2882981 | 0.80 | SLC6A3 (0.54) | — | |
| SCHEMBL2880558 | 0.80 | OPRL1 (0.51) | OPRL1KCNH2SIGMAR1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | OPRL1 1/4885KCNH2 969/4885SIGMAR1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.